Physician profile
Reena Thomas
NPI 1861626939
$3,894.41
in general payments reported to CMS, 2019-2025
21 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $224 · 2021: $564 · 2022: $720 · 2023: $977 · 2024: $186 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.41 | 2021-2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $480.80 | 2019-2023 | Austedo Xr |
| Corium, LLC | $426.44 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $378.56 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $272.37 | 2019-2021 | |
| Neos Therapeutics, Lp | $262.90 | 2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Allergan, INC. | $242.15 | 2019-2020 | |
| Axsome Therapeutics, INC. | $239.54 | 2023 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $134.71 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $121.64 | 2022 | |
| Neurocrine Biosciences, INC. | $114.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $108.97 | 2019 | |
| Tris Pharma INC | $104.30 | 2025 | Onyda Xr |
| Ucb, INC. | $97.88 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $93.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.88 | 2019 | |
| Glaxosmithkline, LLC. | $23.76 | 2019 | |
| Abbott Laboratories | $16.96 | 2023 | Prodigy |
| Medtronic Vascular, INC. | $14.22 | 2020 | |
| Medtronic, INC. | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.